Loading
The Paris System is how a urine cytology report is worded, and it is built to answer one question: are there cells of high-grade bladder cancer?
The second edition of the Paris System (Wojcik and colleagues, Journal of the American Society of Cytopathology 2022; 65 authors from 33 countries) keeps the focus of urine cytology on detecting high-grade urothelial carcinoma. Low-grade lesions are placed in the category negative for high-grade urothelial carcinoma. Each diagnostic category carries a risk of high-grade malignancy that guides management, and the edition adds a chapter on urine from the upper urinary tract.
Showing the technology this term belongs to: Urine tests for bladder cancer (cytology, FISH, RNA and methylation).
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology).
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology).
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology).
Shares WHO Reporting Systems for cytopathology, Bethesda category (thyroid cytology).
Shares Urine tests for bladder cancer (cytology, FISH, RNA and methylation), Bladder & urothelial cancer.
Shares Urine tests for bladder cancer (cytology, FISH, RNA and methylation), Bladder & urothelial cancer.
Shares Urine tests for bladder cancer (cytology, FISH, RNA and methylation), Bladder & urothelial cancer.
Shares Urine tests for bladder cancer (cytology, FISH, RNA and methylation), Bladder & urothelial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/